Zeynep Ecem Kain
YOU?
Author Swipe
View article: HER2-low breast cancer in routine practice: a nationwide study of diagnostic variability across pathology laboratories
HER2-low breast cancer in routine practice: a nationwide study of diagnostic variability across pathology laboratories Open
Patients with HER2-low breast cancer (BC) may be eligible for trastuzumab-deruxtecan (T-DXd) treatment. However, studies have shown that different HER2 antibodies vary in their sensitivity for low HER2 expression, potentially impacting HER…
View article: Decision‐making in breast pathology reporting: the effect of clinical relevant thresholds
Decision‐making in breast pathology reporting: the effect of clinical relevant thresholds Open
Aims In breast cancer (BC) pathology reports, small differences around cut‐off values can impact staging and consequently, clinical decision‐making. Several pathology variables are not very exact, leaving room for interpretation by the pat…
View article: Role of immunohistochemistry in the differential diagnosis of pediatric renal tumors: expression of cyclin d1, beta-catenin , pdgfr-alpha, and pten
Role of immunohistochemistry in the differential diagnosis of pediatric renal tumors: expression of cyclin d1, beta-catenin , pdgfr-alpha, and pten Open
Cyclin D1 is not a specific immunohistochemical marker due to its strong and diffuse positivity in CCS cases. It may be useful to differentiate CCS from blastemal and stromal components of WT. Other markers except cyclin D1 do not have a r…
View article: Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis
Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis Open
Aim: We aimed to show the immunohistochemical expression of programmed death ligand 1 (PD-L1) in laryngeal squamous cell carcinomas (SCCs). Materials and methods: The study includes 52 laryngeal SCC cases that underwent surgical resection.…